Paediatric Vaccine Market Set to Surge to USD 223.8 Billion by 2035, Driven by Innovation and Global Demand

The global paediatric vaccine market is preparing to enter a transformative decade, marked by unprecedented expansion, groundbreaking innovations, and heightened collaboration between established pharmaceutical leaders and emerging manufacturers. According to recent analysis, the market is estimated at USD 69.2 billion in 2025 and is projected to reach USD 223.8 billion by 2035, reflecting a robust compound annual growth rate of 12.4 percent. This growth is supported by a convergence of technological progress, global health initiatives, and the collective determination of industry stakeholders to safeguard children against life-threatening diseases.

At the heart of this surge lies the pivotal role of vaccines in reducing childhood mortality and morbidity. National immunization programs, strengthened by WHO recommendations and government-led campaigns, have paved the way for broader access to paediatric vaccines. These initiatives are complemented by rising parental awareness and global recognition of preventive healthcare as a priority, ensuring demand remains strong across both developed and developing regions.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-1317

Leading Segments in the Market

Pneumococcal Conjugate Vaccines

One of the central narratives shaping this market is the leadership of pneumococcal conjugate vaccines, which are forecast to represent 18.6 percent of paediatric vaccine revenues in 2025. Pneumococcal infections continue to be among the leading causes of illness and death among children under five, making this vaccine category indispensable. Backed by extensive clinical validation and widespread government endorsement, pneumococcal vaccines have become an integral part of routine immunization schedules, particularly in regions where respiratory infections place immense pressure on healthcare systems.

Live or Attenuated Vaccines

Technological innovations also continue to redefine the market. Live attenuated vaccines are expected to command 27.3 percent of the global share in 2025, underscoring their proven efficacy in generating durable immune responses with fewer doses. Their role in combating measles, mumps, rubella, and other infectious diseases reflects decades of scientific achievement. Modern research continues to enhance safety, efficacy, and delivery methods, further solidifying their importance in paediatric immunization.

Multivalent Vaccines

Multivalent vaccines are set to dominate with 61.5 percent of revenue in 2025, reflecting the efficiency and practicality of combining multiple protections in a single dose. These innovations reduce the logistical burden on healthcare systems and improve compliance among children and parents, representing a significant step forward in public health outcomes.

Historical Performance and Future Forecast

Historical performance underscores this momentum. Between 2020 and 2025, the market grew at a rate of 9.7 percent, fueled in part by heightened global awareness during the COVID-19 pandemic. While initial phases of the pandemic disrupted routine immunization, they also reinforced the indispensable value of vaccines in disease prevention. By 2035, the market is projected to expand with a CAGR exceeding 13 percent, signaling the sustained role of innovation, investment, and government commitment in driving long-term growth.

Regional Insights

Regionally, North America and Europe continue to lead, together accounting for over half of the market share in 2025. The United States alone represents 17.9 percent, propelled by cutting-edge healthcare infrastructure and substantial investments in R&D. In Europe, the United Kingdom is expected to see rapid expansion, supported by government-led immunization initiatives.

Asia-Pacific is expected to witness the most dynamic growth, with China holding 19.6 percent and India 19.2 percent of the global market share in 2025. These countries’ large populations and rising healthcare expenditures make them critical markets for manufacturers seeking both scale and opportunity. Australia also contributes significantly, with 9.4 percent of the global share, underscoring its proactive approach to disease prevention.

Competitive Landscape

The industry’s competitive landscape is characterized by both established giants and innovative challengers. GlaxoSmithKline, Merck & Co., Pfizer, and Sanofi remain at the forefront, leveraging decades of expertise, expansive distribution networks, and strong regulatory track records. Regional leaders such as Serum Institute of India, Bharat Biotech, and Panacea Biotec are asserting themselves with cost-effective solutions and strong government backing. Emerging players like Zydus Cadila and Meissa Vaccines Inc. are making waves with groundbreaking R&D programs, particularly in RSV vaccines. International suppliers such as Catalent, Robinson Pharma, and Sirio Pharma are contributing by strengthening production capacity and enhancing delivery systems.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1317

Recent Developments

Recent developments highlight the dynamism of the market. In June 2025, SK Bioscience and Sanofi Pasteur reported promising data on a 21-valent pneumococcal conjugate vaccine study. Around the same time, GSK and Pfizer achieved FDA approvals for vaccines targeting RSV, expanding the scope of paediatric care. Meissa Vaccines Inc. also announced encouraging results for its RSV candidate, while Pfizer and BioNTech secured FDA approval for COVID-19 booster doses for adolescents aged 12 and above.

Future Trends and Innovations

Next-generation formulations are expected to drive future growth. Gene-based vaccines utilizing DNA and RNA technology are gaining traction, building on the scientific breakthroughs achieved during the COVID-19 pandemic. Combination and bivalent vaccines, offering multiple protections in a single shot, are gaining momentum as healthcare providers and parents embrace their convenience and efficacy.

Institutional healthcare centers account for 72.9 percent of vaccine administration in 2025, reflecting the critical role of trained professionals. Outreach programs in underserved regions are expanding access, highlighting the market’s commitment to global equity in child healthcare.

Related Reports:

Cytomegalovirus Treatment Market: https://www.futuremarketinsights.com/reports/cytomegalovirus-treatment-market

Dental Lasers Market: https://www.futuremarketinsights.com/reports/dental-lasers-market

Seasonal Affective Disorder Therapeutics Market: https://www.futuremarketinsights.com/reports/seasonal-affective-disorder-therapeutics-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:     

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube